Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 20 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q1 2023
Institutional positions in Pharvaris N.V. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −4 vs. Q4 2022
- Shares held
- 21.8M
- +479.6K (+2.3%) vs. Q4 2022
- Total value
- $173.9M
- −$65.8M (−27.4%) vs. Q4 2022
- New holders
- 0
- 5 more added
- Sold out
- 4
- 5 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,246,926 | $26.2M | 13.57% | 00.0% | Unchanged |
| FMR LLC | 3,315,238 | $25.9M | 0.00% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $25.6M | 3.20% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,231,923 | $25.3M | 0.12% | 00.0% | Unchanged |
| General Atlantic LLC | 2,420,155 | $19.5M | 0.23% | 00.0% | Unchanged |
| venBio Partners LLC | 2,278,575 | $18.4M | 10.17% | −18,135−0.8% | Reduced |
| Novo Holdings A/S | 1,329,325 | $10.7M | 0.76% | +142,018+12.0% | Added |
| Cormorant Asset Management, LP | 816,460 | $6.58M | 0.43% | 00.0% | Unchanged |
| 5AM Venture Management, LLC | 587,600 | $4.73M | 1.21% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 559,387 | $4.51M | 2.02% | +459,387+459.4% | Added |
| Soleus Capital Management, L.P. | 336,900 | $2.71M | 0.34% | +26,900+8.7% | Added |
| Sio Capital Management, LLC | 228,385 | $1.84M | 0.91% | −56,615−19.9% | Reduced |
| Walleye Capital LLC | 109,945 | $859.8K | 0.02% | −41,384−27.3% | Reduced |
| Morgan Stanley | 48,985 | $394.6K | 0.00% | +10,805+28.3% | Added |
| Foresite Capital Management V, LLC | 34,142 | $275.0K | 0.20% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 26,225 | $211.2K | 0.18% | +900+3.6% | Added |
| Geode Capital Management, LLC | 18,643 | $145.8K | 0.00% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 11,500 | $92.6K | 0.00% | −4,800−29.4% | Reduced |
| UBS Group AG | 422 | $3.40K | 0.00% | −2,378−84.9% | Reduced |
| BlackRock Inc. | 156 | $1.26K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1 | $8 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −12,993−100.0% | Sold out |
| Quantamental Technologies LLC | 0 | $0 | 0.00% | −12,900−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −10,286−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −880−100.0% | Sold out |